Preventing Acute Exacerbations through Novel
Insights in Treatment Strategies for COPD

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AstraZeneca and GlaxoSmithKline

Chronic Obstructive Pulmonary Disease (COPD) is an incurable and progressive disease so early diagnosis is very important to decrease lung damage, improve patient quality of life, and reduce costs. Unfortunately, COPD is substantially under-diagnosed, undertreated, and is devalued as a major health issue. A major advance in COPD management is the recognition that COPD exacerbations can be prevented, and that individuals at risk for first or recurrent exacerbations can be identified sooner than later. The guidelines also recommend all healthcare professionals who treat COPD patients choose an appropriate treatment regimen that may include pharmacologic and non-pharmacologic therapies based on personalized and individual assessment results according to their diagnosis. Pharmacologic agents most commonly used to manage the disease include bronchodilators (beta agonists and anticholinergics), phosphodiesterase-4 inhibitors, antibiotics, and corticosteroids (inhaled and oral). Symptom relief can be achieved through first line therapy with short-acting beta agonists or for long time control with long-acting beta agonists and short- and long-acting anticholinergics. There are also combined therapies that will help manage COPD. Inhaled corticosteroids are recommended as an adjunct therapy to long-acting bronchodilators as well in patients with severe COPD and with a history of repeat exacerbations. Novel treatment options, including biologic and combination therapies, have shown promise in helping to reduce exacerbations.

Upon Completion of this activity, participants will be able to:

  • Assess personalized management plans to reflect guideline recommendations and patient-specific factors including staging, symptom severity, risks of exacerbations, and comorbidities

  • Identify appropriate diagnostic methods of COPD based on a comprehensive assessment of symptoms, risk factors, and spirometry results

  • Discuss key findings from recent clinical trials on the efficacy, safety, and utility of new and emerging therapies for COPD

  • Explore the impact of current and novel COPD pharmacologic agents, considering cost-effective prevention strategies such as smoking cessation

  • Analyze effective treatment plans to prevent exacerbations in patients with COPD, based on current clinical evidence

Faculty: James F. Donohue, MD
Professor of Medicine
University of North Carolina School of Medicine
Division of Pulmonary Diseases
Division of Critical Care Medicine


Dr. Donohue serves on advisory boards/panels for AstraZeneca, DMC and Gilead and serves as a consultant to AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Sunovion. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.  Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AstraZeneca and GlaxoSmithKline

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue